ReviewTrends in molecular medicine2017
Precision Oncology: The Road Ahead.
Review in Trends in molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis.BMC medicine · 2022Pooled it
- Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.JCO precision oncology · 2021Trial
- Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials.Lab on a chip · 2020Trial
- Critical Questions in Genomic Diagnostics for Veterinary Oncology: What We Need to Know.Veterinary and comparative oncology · 2026Review
- Multimodal interpretable deep learning for transcriptome-informed precision oncology and drug mechanism analysis.NPJ digital medicine · 2026Article
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- CSIE: cancer subtyping via inference and ensemble.Briefings in bioinformatics · 2026Article
- Article
- Unveiling personalised targets of PD-1 blockade hyperprogression in a cervical adenocarcinoma via longitudinal single-cell and spatial monitoring.NPJ precision oncology · 2026Article
- Benchmarking community drug response prediction models: datasets, models, tools, and metrics for cross-dataset generalization analysis.Briefings in bioinformatics · 2026Article
- Tackling cancer heterogeneity with systemically delivered oncolytic adenoviruses transcriptionally targeted with hybrid promoters.Molecular therapy. Oncology · 2025Article
- DSCC: disease subtyping using spectral clustering and community detection from consensus networks.Briefings in bioinformatics · 2025Article
- Review
- Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.International journal of environmental research and public health · 2025Review
- Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.bioRxiv : the preprint server for biology · 2025Article
- Computational frameworks transform antagonism to synergy in optimizing combination therapies.NPJ digital medicine · 2025Review
- Article
- Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer.Advances in biomarker sciences and technology · 2025Article
- From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Genomic medicine advances for brain tumors.International journal of clinical oncology · 2024Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Current efforts in precision oncology largely focus on the benefit of genomics-guided therapy. Yet, advances in sequencing techniques provide an unprecedented view of the complex genetic and nongenetic heterogeneity within individual tumors. Herein, we outline the benefits of integrating genomic and transcriptomic analyses for advanced precision oncology. We summarize relevant computational approaches to detect novel drivers and genetic vulnerabilities, suitable for therapeutic exploration. Clinically relevant platforms to functionally test predicted drugs/drug combinations for individual patients are reviewed. Finally, we highlight the technological advances in single cell analysis of tumor specimens. These may ultimately lead to the development of next-generation cancer drugs, capable of tackling the hurdles imposed by genetic and phenotypic heterogeneity on current anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.